Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDXNASDAQ:INVANASDAQ:NVAXNASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$19.57-0.1%$19.21$14.40▼$47.00$1.30B1.59879,358 shs377,561 shsINVAInnoviva$18.24-0.8%$17.75$14.95▼$21.28$1.14B0.48630,525 shs419,440 shsNVAXNovavax$6.67-5.7%$7.13$4.10▼$23.86$1.07B3.158.34 million shs13.15 million shsVSTMVerastem$7.50$6.06$2.10▼$13.52$386.18M0.571.00 million shs1.80 million shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics0.00%+6.94%-1.81%-20.25%-46.09%INVAInnoviva0.00%-0.16%+0.33%-3.90%+19.53%NVAXNovavax0.00%+11.17%-4.71%-28.43%+63.08%VSTMVerastem0.00%+30.66%+21.16%+31.83%-20.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDXCelldex Therapeutics1.9938 of 5 stars4.40.00.00.03.60.00.0INVAInnoviva4.1879 of 5 stars3.50.00.04.22.92.51.9NVAXNovavax3.5244 of 5 stars3.21.00.04.72.60.80.6VSTMVerastem2.9736 of 5 stars4.51.00.00.02.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.89Moderate Buy$54.33177.64% UpsideINVAInnoviva 3.00Buy$55.00201.54% UpsideNVAXNovavax 2.43Hold$18.00169.87% UpsideVSTMVerastem 3.00Buy$13.8985.19% UpsideCurrent Analyst Ratings BreakdownLatest VSTM, CLDX, INVA, and NVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025VSTMVerastemJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/9/2025VSTMVerastemMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.003/24/2025VSTMVerastemGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $14.003/24/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.003/21/2025VSTMVerastemRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.003/20/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$46.003/7/2025INVAInnovivaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$55.003/3/2025CLDXCelldex TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$42.00 ➝ $36.002/28/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.002/28/2025NVAXNovavaxBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.002/27/2025NVAXNovavaxTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.02M185.06N/AN/A$9.08 per share2.16INVAInnoviva$358.71M3.19$3.53 per share5.17$10.66 per share1.71NVAXNovavax$682.16M1.57N/AN/A($6.04) per share-1.10VSTMVerastem$10M38.62N/AN/A$2.27 per share3.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$141.43M-$2.45N/AN/AN/A-1,544.32%-19.75%-18.86%5/5/2025 (Estimated)INVAInnoviva$179.72M$0.1926.4411.77N/A18.31%20.84%11.38%5/6/2025 (Estimated)NVAXNovavax-$545.06M-$1.33N/A83.382.85-32.18%N/A-17.05%5/9/2025 (Estimated)VSTMVerastem-$87.37M-$3.50N/AN/AN/AN/A-332.73%-73.97%5/8/2025 (Estimated)Latest VSTM, CLDX, INVA, and NVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025NVAXNovavax$0.19N/AN/AN/A$204.08 millionN/A5/8/2025Q1 2025VSTMVerastem-$0.65N/AN/AN/A$0.10 millionN/A5/5/2025Q1 2025CLDXCelldex Therapeutics-$0.75N/AN/AN/A$1.08 millionN/A3/20/2025Q4 2024VSTMVerastem-$0.76-$1.33-$0.57-$1.33$0.15 millionN/A2/27/2025Q4 2024CLDXCelldex Therapeutics-$0.73-$0.71+$0.02-$0.71$1.25 million$1.18 million2/27/2025Q4 2024NVAXNovavax-$0.75-$0.51+$0.24-$0.51$85.48 million$88.31 million2/26/2025Q4 2024INVAInnovivaN/A$0.57N/A$0.26N/A$91.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A24.2724.27INVAInnoviva0.381.791.64NVAXNovavaxN/A0.930.93VSTMVerastem2.773.233.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/AINVAInnoviva99.12%NVAXNovavax53.04%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics3.80%INVAInnoviva2.25%NVAXNovavax1.00%VSTMVerastem2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.38 million63.82 millionOptionableINVAInnoviva10062.68 million61.54 millionOptionableNVAXNovavax1,990160.84 million158.58 millionOptionableVSTMVerastem5051.49 million43.53 millionOptionableVSTM, CLDX, INVA, and NVAX HeadlinesRecent News About These CompaniesVerastem, Inc. (NASDAQ:VSTM) Shares Bought by Geode Capital Management LLCApril 28 at 3:24 AM | marketbeat.comMarshall Wace LLP Invests $4.10 Million in Verastem, Inc. (NASDAQ:VSTM)April 27 at 4:33 AM | marketbeat.comVerastem Oncology Announces $75 million Private Placement | VSTM Stock NewsApril 25 at 5:43 PM | gurufocus.comVerastem Oncology Announces $75 million Private PlacementApril 25 at 5:42 PM | gurufocus.comVerastem Oncology Announces $75 million Private PlacementApril 25 at 10:20 AM | finance.yahoo.comVerastem Oncology rises on $75M private placementApril 25 at 9:19 AM | seekingalpha.comVerastem announces U.S. IND clearance of VS-7375April 25 at 12:17 AM | markets.businessinsider.comVerastem, Inc. (NASDAQ:VSTM) Shares Sold by Walleye Capital LLCApril 24, 2025 | marketbeat.comVerastem Oncology Receives FDA Clearance for Investigational New Drug Application for Cancer TreatmentApril 23, 2025 | marketwatch.comVerastem Oncology to initiate trial for its targeted cancer therapyApril 23, 2025 | msn.comVerastem (VSTM) Gains FDA Nod for Novel Cancer Drug VS-7375April 23, 2025 | gurufocus.comVerastem (VSTM) Advances VS-7375 for Cancer Treatment with FDA Approval | VSTM Stock NewsApril 23, 2025 | gurufocus.comVerastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, ...April 23, 2025 | gurufocus.comVerastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid TumorsApril 23, 2025 | businesswire.comVerastem Oncology to Report Q1 Earnings: What's in the Cards?April 22, 2025 | finance.yahoo.comVerastem (NASDAQ:VSTM) Cut to Sell at StockNews.comApril 21, 2025 | americanbankingnews.comVerastem (NASDAQ:VSTM) Rating Lowered to Sell at StockNews.comApril 20, 2025 | marketbeat.comVerastem, Inc. (NASDAQ:VSTM) Position Trimmed by Kennedy Capital Management LLCApril 18, 2025 | marketbeat.comTop Cancer Stocks to Buy to Boost Your Portfolio's HealthApril 16, 2025 | zacks.comVerastem, Inc. (NASDAQ:VSTM) Given Consensus Recommendation of "Buy" by AnalystsApril 15, 2025 | marketbeat.comMizuho Lowers Verastem (NASDAQ:VSTM) Price Target to $8.00April 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVSTM, CLDX, INVA, and NVAX Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$19.57 -0.01 (-0.05%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$19.58 +0.01 (+0.05%) As of 04/25/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Innoviva NASDAQ:INVA$18.24 -0.14 (-0.76%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$18.24 0.00 (0.00%) As of 04/25/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Novavax NASDAQ:NVAX$6.67 -0.40 (-5.66%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$6.60 -0.06 (-0.97%) As of 04/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.Verastem NASDAQ:VSTM$7.50 0.00 (0.00%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$7.47 -0.03 (-0.35%) As of 04/25/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
